Title:
IL-17RA ANTIBODY FC FUSION PROTEIN, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/194311
Kind Code:
A2
Abstract:
Provided are an IL-17RA antibody Fc fusion protein, a pharmaceutical composition, an injection, and a use thereof. The IL-17RA fusion protein comprises connection-operatable, sequentially and serially connected signal peptides, an IL-17RA extracellular domain, and an IgG1 constant region. The IL-17RA fusion protein of the present invention has an extended half-life, obtains longer-acting drug activity and lowered immunogenicity compared to antibody medications. The design of the present invention allows the IL-17RA fusion protein to eliminate ADCC, ADCP, and CDC effect, retains the in-vivo recycling mediated by Fc receptors (FcRn) in newborns, and has lower side reaction and is safer compared to current commercially available IL-17RA antibodies.
Inventors:
ZHANG YUNTAO (CN)
WANG JIAN (CN)
LIU JIANWEI (CN)
YAN JIALI (CN)
GUO BEILEI (CN)
LIU MINGYANG (CN)
LI SUZHEN (CN)
LIU SEN (CN)
CHAO HUA (CN)
GU QIONG (CN)
QI FANGBING (CN)
LEI YONGPENG (CN)
LU HUI (CN)
WANG JIAN (CN)
LIU JIANWEI (CN)
YAN JIALI (CN)
GUO BEILEI (CN)
LIU MINGYANG (CN)
LI SUZHEN (CN)
LIU SEN (CN)
CHAO HUA (CN)
GU QIONG (CN)
QI FANGBING (CN)
LEI YONGPENG (CN)
LU HUI (CN)
Application Number:
PCT/CN2022/100748
Publication Date:
September 22, 2022
Filing Date:
June 23, 2022
Export Citation:
Assignee:
NAT VACCINE AND SERUM INSTITUTE (CN)
VALIN TECH LTD (IL)
VALIN TECH LTD (IL)
Attorney, Agent or Firm:
TEE&HOWE INTELLECTUAL PROPERTY ATTORNEYS (CN)
Download PDF: